Clinical Computing PLC
01 September 2003
1 September 2003
Clinical Computing Plc (the 'Company')
Result of Extraordinary General Meeting
The Company announces that at the Extraordinary General Meeting which took place
earlier today, all resolutions proposed to shareholders were duly passed.
In his statement to shareholders, Howard Kitchner, Chairman said: 'We are
pleased to announce a recent contract signing with the University of Louisville,
Kidney Disease Program, a legacy customer of the Company. The University of
Louisville represents the first di-PROTONTM customer to migrate to Clinical
VisionTM. The Group, upon go-live of this system, will have converted customers
to Clinical VisionTM from each of its legacy product lines, ProtonTM, di-PROTON
TM and RENLStarTM.'
'This contract win is consistent with our short term goal of capitalising on our
existing relationships in the renal market.'
Enquiries
Clinical Computing plc Tel: 020 78747 8744
Joseph Marlovits, Company Secretary joe.marlovits@ccl.com
Investec Investment Banking Tel: 020 7597 5970
Nigel Tose, Co Head of Corporate Finance
Andrew Craig
Binns & Co PR Ltd Tel: 020 7786 9600
Peter Binns
Paul McManus
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.